Analyst forecasts - Smiths Group plc


The cookie settings on this website are set to ‘allow all cookies’. Leaving your settings to ‘allow all cookies’ means you consent to a website remembering your preferences and generally enhancing the user experience. If you prefer a website to not remember your preferences, you can change your settings at any time by changing the privacy settings of your browser.

Find out more about cookies >

Analyst forecasts

Consensus FY17
John Crane 843
Medical 954
Detection 601
Interconnect 478
Flek-Tek 314
Revenue (£m) 3,189
John Crane 184
Medical 201
Detection 79
Interconnect 63
Flek-Tek 57
Central -40
Headline operating profit (£m)* 544
Net Financing -63
Headline PBT (£m)* 489
Tax rate 26.0%
Tax -125
Headline PAT (£m) 356
Headline EPS 89.8p

Updated 14 November 2016

* Headline profit is before exceptional items, amortisation and impairment of acquired intangible assets, pension charges and financing gains/losses from currency hedging.

Consensus estimates above exclude the proposed acquisition of Morpho Detection.

Each line is the average for the analysts’ forecasts for that item and as such the numbers do not always total correctly because of rounding differences.



The forecasts in this analysis have been gathered from a number of registered investment analysts and are, as such, publicly available information. These estimates are forward looking and are therefore subject to risks and uncertainties that may materially affect eventual results. In distributing this analysis, Smiths Group does not imply its endorsement of, or concurrence with, such information, conclusions or recommendations. Nothing in this analysis should be taken as a recommendation to buy or sell shares in Smiths Group or to take any other action or place any reliance on the analysis. Smiths Group is not regulated by the Financial Conduct Authority and cannot offer investment advice.

Although Smiths Group will endeavour to procure that the information is kept updated, Smiths Group assumes no obligation to update or revise such information to reflect circumstances existing after the date hereof. Neither Smiths Group nor any subsidiary undertaking or any director, officer or employee of Smiths Group accepts any responsibility for the accuracy of the forecasts used in this analysis and therefore shall have no liability whatsoever for the consequences of any reliance or actions taken or not taken based on any of the information in this analysis.


Analyst coverage of Smiths Group

House Analyst
Bank of America Merrill Lynch Alex Virgo
Credit Suisse Andre Kukhnin
Deutsche Bank Jonathan Hurn
Exane BNP Paribas Jonathan Mounsey
HSBC Scott Cagehin
Investec Michael Blogg
Jefferies Sandy Morris
JP Morgan Cazenove Glen Liddy
Morgan Stanley Robert Davies
Numis David Larkam
Panmure Gordon Sanjay Jha
Societe Generale Alasdair Leslie
Stifel Mark Davies-Jones
UBS Mark Fielding

back to top

Smiths Group divisions:

John Crane, Smiths Medical, Smiths Detection, Smiths Interconnect, Flex-Tek

Smiths Group plc:
Registered office 4th Floor, 11-12 St James’s Square, London, SW1Y 4LB
Incorporated in England No. 137013
Copyright 2017 Smiths Group plc.
All rights Reserved | Legal Notice | Privacy Policy | Cookie Policy